GSK offers pilots a Chantix alternative

Exploiting a competitor's weakness is a time-honored tradition in business. So it's probably no surprise that GlaxoSmithKline is injecting itself into the Chantix upheaval. You'll recall that last week the FAA told pilots and air traffic controllers they can't use the stop-smoking drug because of new links to accidents, dizziness, and other side effects. (Chantix's potential to cause psychiatric effects is already on the books.) Well, just before the holiday weekend, GSK offered its own stop-smoking product, Commit nicotine lozenges, to pilots and controllers for free. "It seemed to make sense to us to step up and offer this," Bill Slivka, VP for smoking control at GSK's consumer health unit, told the WSJ Health Blog.

- see the item at the Health Blog

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.